Stoke Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Stoke Therapeutics, Inc. (STOK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 178.00 thousand shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2021-03-09
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2020 was 178.00K shares, a 87.82% increase from fiscal 2019.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2019 was 94.77K shares, a 648.00% increase from fiscal 2018.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2018 was 12.67K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|
| 2020-12-31 | 178.00K shares 10-K · filed 2021-03-09 | |
| 2019-12-31 | 94.77K shares 10-K · filed 2021-03-09 | |
| 2019-06-30 | 9.65K shares 10-Q · filed 2019-08-14 | |
| 2018-12-31 | 12.67K shares 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |